Research Output per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 19 Similar Profiles
Tuberculosis
Medicine & Life Sciences
rifapentine
Medicine & Life Sciences
Pyrazinamide
Medicine & Life Sciences
Rifampin
Medicine & Life Sciences
Mycobacterium tuberculosis
Medicine & Life Sciences
Multidrug-Resistant Tuberculosis
Medicine & Life Sciences
Pharmaceutical Preparations
Medicine & Life Sciences
Linezolid
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1999 2019
Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection
Kaushik, A., Ammerman, N., Tyagi, S., Saini, V., Vervoort, I., Lachau-Durand, S., Nuermberger, E. & Andries, K., Apr 1 2019, In : Antimicrobial agents and chemotherapy. e00007-19.Research output: Contribution to journal › Article
Open Access
bedaquiline
Latent Tuberculosis
Injections
rifapentine
Lung
High-dose rifamycins enable shorter oral treatment in a murine model of mycobacterium ulcerans disease
Omansen, T. F., Almeida, D., Converse, P. J., Li, S. Y., Lee, J., Stienstra, Y., van der Werf, T., Grosset, J. H. & Nuermberger, E., Feb 1 2019, In : Antimicrobial Agents and Chemotherapy. 63, 2, e01478-18.Research output: Contribution to journal › Article
rifapentine
Rifamycins
Mycobacterium ulcerans
Rifampin
Buruli Ulcer
In vitro activity of the new -lactamase inhibitors relebactam and vaborbactam in combination with -lactams against mycobacterium abscessus complex clinical isolates
Kaushik, A., Ammerman, N., Lee, J., Martins, O., Kreiswirth, B. N., Lamichhane, G., Parrish, N. M. & Nuermberger, E., Mar 1 2019, In : Antimicrobial agents and chemotherapy. e02623-18.Research output: Contribution to journal › Article
Lactams
Mycobacterium
meropenem
Cefuroxime
Carbapenems
One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis
BRIEF TB/A5279 Study Team, Mar 14 2019, In : New England Journal of Medicine. 380, 11, p. 1001-1011 11 p.Research output: Contribution to journal › Article
rifapentine
Isoniazid
Tuberculosis
HIV
Confidence Intervals
Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer
Almeida, D. V., Omansen, T. F., Li, S. Y., Lee, J., Grosset, J. H., Converse, P. J. & Nuermberger, E., Mar 1 2019, In : Antimicrobial agents and chemotherapy. e02171-18.Research output: Contribution to journal › Article
Buruli Ulcer
Linezolid
Oxazolidinones
Clarithromycin
Rifampin